Johnson & Johnson logo

Johnson & Johnson (JNJ) Q3 2024 Earnings

JNJ·Reported October 15, 2024·Before market open

Johnson & Johnson reported Q3 2024 revenue of $22.5B, beat analyst consensus of $22.2B by $299.2M. Diluted EPS came in at $2.42, beat the $2.21 consensus by $0.21. Johnson & Johnson reports across 2 business segments, led by Innovative Medicine and MedTech.

Revenue
$22.5Bbeat by $299.2M
Consensus: $22.2B
Diluted EPS
$2.42beat by $0.21
Consensus: $2.21
SEC

SEC Filings

Earnings release8-K · 0000200406-24-000088
Quarterly report10-Q · 0000200406-24-000096

Financial Snapshot

Trailing eight quarters through Q3 2024

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q3 2024 Earnings FAQ

Common questions about Johnson & Johnson's Q3 2024 earnings report.

Johnson & Johnson (JNJ) reported Q3 2024 earnings on October 15, 2024 before market open.

Johnson & Johnson reported revenue of $22.5B and diluted EPS of $2.42 for Q3 2024.

Revenue beat the consensus estimate of $22.2B by $299.2M. EPS beat the consensus estimate of $2.21 by $0.21.

You can read the 8-K earnings release (0000200406-24-000088) and the 10-Q periodic report (0000200406-24-000096) directly on SEC EDGAR. The filing index links above go to sec.gov.